drugset
drugset / Trial / NCT00750698

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

NCT00750698 ↗

Phase 2 Terminated 8 enrolled Syndax Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the tumor responses to SNDX-275 (entinostat) in combination with continued erlotinib in participants with non-small Cell Lung Carcinoma (NSCLC) who are progressing on erlotinib.

Timeline

Start
2008-08
Primary completion
2010-05
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Entinostat Small molecule 10 mg Oral
Background Erlotinib Small molecule 150 mg Oral

Indications

non-small cell lung carcinoma